MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma

Cancer Science. 2014 April 23. [Epub ahead of print] [Link]

Gotoh A, Kaku Y, Kanno T, NagayaH, Nakano T, Nakao S, Nishizaki T, Shimizu T, Tabata C, Tanaka A, Tsuchiya A.

Abstract

The newly synthesized naftopidil analogue HUHS1015 reduced cell viability in malignant pleural mesothelioma cell lines such as MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452 cells, with the potential greater than that for the anticancer drugs paclitaxel or cisplatin at higher concentrations more than 30 μM. HUHS1015 induced both necrosis and apoptosis of MSTO-211H and NCI-H2052 cells. HUHS1015 upregulated expression of mRNAs for Puma, Hrk, and Noxa in MSTO-211H and NCI-H2052 cells, suggesting HUHS1015-induced mitochondrial apoptosis. HUHS1015 clearly suppressed tumor growth in mice inoculated with NCI-H2052 cells. Taken together, the results of the present study indicate that HUHS1015 could be developed as an effective anticancer drug for treatment of malignant pleural mesothelioma.

Both comments and trackbacks are currently closed.